Equity Overview
Price & Market Data
Price: $1.84
Daily Change: -$0.04 / 2.17%
Daily Range: $1.83 - $1.90
Market Cap: $130,694,304
Daily Volume: 496,254
Performance Metrics
1 Week: 0.55%
1 Month: -2.13%
3 Months: -5.64%
6 Months: -2.65%
1 Year: -26.98%
YTD: -26.10%
Company Details
Employees: 157
Sector: Health technology
Industry: Biotechnology
Country:
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.